INmune Bio Stock Discussion

$INmune Bio (INMB.US)$
Patent Win: INmune Bio's Revolutionary Cell Therapy Secures 20+ Years Protection

$INmune Bio (INMB.US)$ INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE

$INmune Bio (INMB.US)$
INmune Bio's Game-Changing Partnership Accelerates CORDStrom Production for 4,000 RDEB Patients

$INmune Bio (INMB.US)$
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness
Monday, 14th April at 8:00 am
Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT Catapult) to establish large-scale, commercial...

$INmune Bio (INMB.US)$ INmune Bio, Inc. (INMB), a clinical-stage immunology company, Tuesday announced that it is presenting findings from its MINDFuL Phase II trial at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) 2025 in Vienna.
The trial focuses on early Alzheimer's disease (AD) patients with confirmed biomarkers of inflammation.
The study enrolled 208 patients, categorized as mild cognitive impairment (MCI, 44%) or mild AD (mAD,...

$INmune Bio (INMB.US)$
Promising Patient Profile Emerges in Major Alzheimer's Drug Trial: 69% Carry Key Risk Gene

$INmune Bio (INMB.US)$
INmune Bio's Triple Threat: Alzheimer's Trial Fully Enrolled, FDA Designations Secured

$INmune Bio (INMB.US)$ Corporate:
● Completed repayment of outstanding Silicon Valley Bank term loan in December.
● Executed securities purchase agreements with new and existing institutional investors and certain directors, officers and employees of the Company for total gross proceeds of approximately $27.5 million. As part of the offerings, the company issued approximately 3.9 million warrants to purchase common stock. The...

$INmune Bio (INMB.US)$
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Monday, 10th February at 7:00 am
• The Company reports results of a double-blinded, randomized, placebo-controlled study, known as "MissionEB," investigating CORDStrom for treatment of RDEB in pediatric patients, which evidence a favorable benefit-risk profile in support of the intended applications...